http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
송태진,김영대,유준상,Jinkwon Kim,장혁재,홍그루,Chi Young Shim,Dongbeom Song,허지회,남효석 대한뇌졸중학회 2016 Journal of stroke Vol.18 No.3
Background and Purpose Cerebral small vessel disease (SVDs) are related with large artery atherosclerosis. However, the association between aortic atheroma (AA) and cerebral small vessel disease has rarely been reported. This study evaluated the relationship between presence and burden of AAs and those of SVDs in patients with acute ischemic stroke. Methods We included 737 consecutive patients who underwent transesophageal echocardiography (TEE) and brain magnetic resonance imaging (MRI) for evaluation of acute stroke. AA subtypes were classified as complex aortic plaque (CAP) and simple aortic plaque (SAP). Presence and burden of SVDs including cerebral microbleeds (CMBs), white matter hyperintensities (WMHs), perivascular spaces (PVSs), asymptomatic lacunar infarctions (ALIs), and total SVD score, were investigated. Results AA was found by TEE in 360 (48.8%) patients including 11.6% with CAP and 37.2% with SAP. One or more types of SVDs was found in 269 (36.4%) patients. In multivariable analysis, presence of CMBs (odds ratio [OR] 4.68), high-grade WMHs (OR 3.13), high-grade PVSs (OR 3.35), and ALIs (OR 4.24) were frequent in patients with AA than those without AA. Each 1-point increase in total SVD score increased the odds of presence of CAP (OR 1.94, 95% confidence interval (CI) 1.44-1.85) and SAP (OR 1.54, 95% CI 1.35-1.75). Conclusions In this study, patients with AA frequently had cerebral SVDs. Larger burden of AA was associated with advanced cerebral SVDs. Our findings give an additional information for positive relationship with systemic atherosclerosis and coexisting cerebral SVDs in acute ischemic stroke patients.
CAD/CAM과 MAD/MAM 시스템으로 제작된 3-unit 지르코니아 고정성 국소의치의 변연 적합도에 관한 연구
송태진,여인성,양재호,Song, Tae-Jin,Yeo, In-Sung,Yang, Jae-Ho 대한치과보철학회 2011 대한치과보철학회지 Vol.49 No.2
연구 목적: 본 연구의 목적은 CAD/CAM과 MAD/MAM 시스템으로 제작된 3-unit 지르코니아 고정성 국소의치의 변연 적합도를 통상적인 방법으로 제작된 금속-도재 고정성 국소의치와 비교 분석하는 것이다. 연구 재료 및 방법: 레진 치아 (상악 중절치와 측절치)를 전부 도재관을 위한 형태로 삭제하고, 이를 인상 채득하여 에폭시 레진 모형을 제작하였다. 이 모형상에서 금속-도재 고정성 국소의치, CAD/CAM 지르코니아 고정성 국소의치 ($Everest^{(R)}$, Kavo Dental GmbH, Biberach, Germany), MAD/MAM 지르코니아 고정성 국소의치 ($Rainbow^{TM}$, Dentium Co. Inc., Seoul, South Korea)를각각5개씩 제작하였다. 제작된 고정성 국소의치를 레진 모형에 접착하고, 가공치 부위를 절단하여, 각각 광학 현미경 (Presize 440C)을이용, 145 배율로 변연 간격을 측정하였다. 측정된 결과는 one-way ANOVA test로 분석하였고, Duncan test로 사후 검정하였다 (${\alpha}$=.05). 결과: 각 군의 변연 간격의 평균과 표준편차는 금속-도재 고정성 국소의치 $78.48{\pm}11.05\;{\mu}m$, $Everest^{(R)}$ 시스템 $59.30{\pm}11.63\;{\mu}m$, $Rainbow^{TM}$ 시스템 $70.34{\pm}13.98\;{\mu}m$로 측정되었다. 결론: 1. $Everest^{(R)}$ 시스템이 금속-도재 고정성 국소의치보다 변연 간격이 작은 것으로 측정되었다 (P<.05). 2. $Everest^{(R)}$ 시스템과 $Rainbow^{TM}$ 시스템간의 변연 적합도는 유의성 있는 차이를 보이지 않았다 (P>.05). 3. $Rainbow^{TM}$ 시스템은 금속-도재 고정성 국소의치와 변연 간격에 유의 차가 없었다 (P>.05). 4. 각 군의 평균 변연 간격이 임상적으로 적합한 범위 내에 ($120\;{\mu}m$) 있었다. Purpose: The purpose of this study was to compare the marginal fit of three-unit zirconia fixed dental prostheses (FDPs) fabricated using CAD/CAM and MAD/MAM system. Materials and methods: Dentiform maxillary central and lateral incisor were prepared for 3-unit FDP and fixed in yellow stone. This model was duplicated to epoxy resin die. On the resin die, fifteen 3-unit FDPs were fabricated. Metal-ceramic group was three-unit metal-ceramic FDPs, $Everest^{(R)}$ group was zirconia three-unit FDPs fabricated using the $Everest^{(R)}$ system (Kavo Dental GmbH, Biberach, Germany) and $Rainbow^{TM}$ group was zirconia three-unit FDPs fabricated using the $Rainbow^{TM}$ system (Dentium Co. Inc., Seoul, South Korea). They were cemented to resin dies with adhesive resin cement. After removing pontics, each retainers were separated and observed under measuring machine (Presize 440C) and analyzed through one-way ANOVA and Duncan test (${\alpha}$ = .05). Results: Mean values and standard deviations of marginal gap dimensions in each group for three-unit FDPs were $78.5{\pm}11.05\;{\mu}m$ for the metal-ceramic group, $59.30{\pm}11.63\;{\mu}m$ for the $Everest^{(R)}$ group and $70.34{\pm}13.98\;{\mu}m$ for the $Rainbow^{TM}$ group. Conclusion: 1. The $Everest^{(R)}$ group in comparison with metal-ceramic group showed better marginal fit, which had significant differences P<.05. 2. The mean marginal gap values between $Everest^{(R)}$ and $Rainbow^{TM}$ group did not showed significant differences (P>.05). 3. The mean marginal gap values between $Rainbow^{TM}$ group and metal-ceramic group did not showed significant differences (P>.05). 4. The mean marginal gaps of each group were within clinically acceptable range ($120\;{\mu}m$).
간세포암과 간내담관암의 7<SUP>th</SUP> AJCC TNM Stage의 소개
송태진(Taejin Song) 한국간담췌외과학회 2010 한국간담췌외과학회지 Vol.14 No.2
Purpose: Cancer staging is essential in clinical cancer practice in medical and surgical oncology. Staging based on the guidelines of the American Joint Committee on Cancer (AJCC) is the most popular and is widely used in clinical fields. Early this year, the 7th edition of the AJCC cancer staging manual was published. I have compared and described the changes in the new edition from the older version to facilitate staging in clinical settings, especially for liver and intrahepatic bile duct malignancies. Methods: On the basis of the new 2010 edition of the 7th AJCC TNM cancer staging manual, I have compared hepatobiliary malignancy in Chapter 18, liver malignancy and intrahepatic bile duct malignancy in Chapter 19. Results: One of the major changes in the 7th AJCC manual compared to the 6th AJCC staging manual published in 2002 is separation of the Liver and Intrahepatic bile duct cancer chapters. In the previous edition, intrahepatic bile duct cancer was included in the liver malignancy chapter. Conclusion: There are no universal and permanent staging systems for cancer. The staging systems are ever changing to adjust for changes in treatment and prognosis of malignancies. We need to collect data in order to modify the staging correctly in collaboration with multi-institutional efforts to reduce biases in staging liver and intrahepatic bile duct cancers.